- In September 2024, BD has been recognized in the top 10 for overall transparency and awarded Best Code of Conduct U.S. Transparency Awards. This accolade underscores BD's commitment to ethical practices, emphasizing clarity and accessibility in its corporate disclosures, which foster trust among stakeholders and reflect the company's core values in health care innovation
- In July 2024, Siemens Healthineers announced the launch of the Atellica AIA, an advanced immunoassay analyzer that enhances laboratory efficiency and accuracy. This innovative system streamlines workflows and improves turnaround times for patient results, positioning Siemens as a leader in diagnostic technology. The upgrade is expected to drive growth by attracting more laboratory partnerships and increasing market share
- In March 2024, Siemens Healthineers unveiled its new Fast Track Diagnostic (FTD) service, designed to accelerate diagnostic processes in healthcare facilities. This service enhances efficiency by reducing turnaround times for test results and optimizing laboratory workflows. By improving patient care and operational performance, Siemens aims to strengthen its market position and attract more healthcare providers seeking advanced diagnostic solutions
- In September 2023, Abbott completed its acquisition of Bigfoot Biomedical, enhancing its diabetes care portfolio with advanced insulin management systems. This move strengthens Abbott's FreeStyle Libre continuous glucose monitoring technology and supports its goal of personalized diabetes management. Financial terms were not disclosed
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE GERMANY, SWITZERLAND AND AUSTRIA DIAGNOSTIC TESTING MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 TESTING SEGMENT LIFELINE CURVE
2.8 MARKET END-USER COVERAGE GRID
2.9 DBMR MARKET POSITION GRID
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
5 THE DIAGNOSTIC TESTING MARKET IN GERMANY, SWITZERLAND, AND AUSTRIA: REGULATIONS
5.1 REGULATIONS IN GERMANY
5.2 REGULATIONS IN AUSTRIA
5.3 REGULATIONS IN SWITZERLAND
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING PREVALENCE OF CHRONIC DISEASES
6.1.2 INCREASE IN THE AGING POPULATION
6.1.3 TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSTICS
6.2 RESTRAINTS
6.2.1 HIGH COST ASSOCIATED WITH DIAGNOSTIC TESTING
6.2.2 LACK OF TRAINED LABORATORY PROFESSIONALS
6.3 OPPORTUNITIES
6.3.1 STRONG HEALTHCARE SYSTEMS AND ADVANCED INFRASTRUCTURE
6.3.2 RISING AWARENESS OF PREVENTATIVE HEALTHCARE
6.3.3 RAPID GROWTH OF PERSONALIZED MEDICINE
6.4 CHALLENGES
6.4.1 STRINGENT RULES & REGULATIONS FOR DIAGNOSTICS PRODUCT APPROVAL
6.4.2 LIMITED BUSINESS EXPANSION CAPABILITY OF NEW ENTRANTS
7 GERMANY, SWITZERLAND, AND AUSTRIA DIAGNOSTIC TESTING MARKET, BY TESTING
7.1 OVERVIEW
7.2 HBA1C TESTING
7.3 AUTOIMMUNE DISORDERS TESTING
7.4 HEMOGLOBIN TESTING
7.5 MYELOMA TESTING
7.6 CARBOHYDRATE-DEFICIENT TRANSFERRIN TESTING
7.7 CSF TESTING
8 GERMANY, SWITZERLAND, AND AUSTRIA DIAGNOSTIC TESTING MARKET, BY DISTRIBUTION CHANNEL
8.1 OVERVIEW
8.2 DIRECT TENDERS
8.3 RETAIL SALES
8.4 OTHERS
9 GERMANY, SWITZERLAND, AND AUSTRIA DIAGNOSTIC TESTING MARKET, BY END USER
9.1 OVERVIEW
9.2 DIAGNOSTICS CENTERS
9.3 DIAGNOSTICS CENTERS
9.4 ACADEMIC AND RESEARCH INSTITUTES
9.5 BLOOD AND TISSUE BANKS
9.6 HOMECARE SETTING
10 GERMANY, SWITZERLAND, AND AUSTRIA DIAGNOSTIC TESTING MARKET, BY MODE OF TESTING
10.1 OVERVIEW
10.2 PRESCRIPTION-BASED TESTING
10.3 OTC -BASED TESTING
11 GERMANY, SWITZERLAND, AND AUSTRIA DIAGNOSTIC TESTING MARKET, BY SAMPLE TYPE
11.1 OVERVIEW
11.2 BLOOD
11.3 CSF
11.4 URINE
11.5 OTHERS
12 GERMANY, SWITZERLAND, AND AUSTRIA DIAGNOSTIC TESTING MARKET, COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: GLOBAL
13 SWOT ANALYSIS
14 COMPANY PROFILES
14.1 F. HOFFMANN-LA ROCHE LTD
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 PRODUCT PORTFOLIO
14.1.4 RECENT DEVELOPMENT
14.2 ABBOTT
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 PRODUCT PORTFOLIO
14.2.4 RECENT DEVELOPMENT
14.3 DANAHER CORPORATION
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 PRODUCT PORTFOLIO
14.3.4 RECENT DEVELOPMENT
14.4 SIEMENS HEALTHINEERS AG
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 PRODUCT PORTFOLIO
14.4.4 RECENT DEVELOPMENT
14.5 BD
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE
14.5.3 PRODUCT PORTFOLIO
14.5.4 RECENT DEVELOPMENT
14.6 A. MENARINI DIAGNOSTICS S.R.L
14.6.1 COMPANY SNAPSHOT
14.6.2 PRODUCT PORTFOLIO
14.6.3 RECENT DEVELOPMENT
14.7 BIO-RAD LABORATORIES
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENT
14.8 BIOMÉRIEUX
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT DEVELOPMENT
14.9 GERMAINE LABORATORIES, INC.
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENT
14.1 QIAGEN
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENT
14.11 QUIDELORTHO CORPORATION
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.12 SYSMEX CORPORATION
14.12.1 COMPANY SNAPSHOT
14.12.2 REVENUE ANALYSIS
14.12.3 PRODUCT PORTFOLIO
14.12.4 RECENT DEVELOPMENT
14.13 THERMO FISHER SCIENTIFIC, INC
14.13.1 COMPANY SNAPSHOT
14.13.2 REVENUE ANALYSIS
14.13.3 PRODUCT PORTFOLIO
14.13.4 RECENT DEVELOPMENT
15 QUESTIONNAIRE
16 RELATED REPORTS
List of Table
TABLE 1 GERMANY DIAGNOSTIC TESTING MARKET, BY TESTING, 2022-2031 (USD MILLION)
TABLE 2 SWITZERLAND DIAGNOSTIC TESTING MARKET, BY TESTING, 2022-2031 (USD MILLION)
TABLE 3 AUSTRIA DIAGNOSTIC TESTING MARKET, BY TESTING, 2022-2031 (USD MILLION)
TABLE 4 GERMANY MYELOMA TESTING IN DIAGNOSTIC TESTING MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 5 SWITZERLAND MYELOMA TESTING IN DIAGNOSTIC TESTING MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 6 AUSTRIA MYELOMA TESTING IN DIAGNOSTIC TESTING MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 7 GERMANY DIAGNOSTIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 8 SWITZERLAND DIAGNOSTIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 9 AUSTRIA DIAGNOSTIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 10 GERMANY DIAGNOSTIC TESTING MARKET, BY END-USER, 2022-2031 (USD MILLION)
TABLE 11 SWITZERLAND DIAGNOSTIC TESTING MARKET, BY END-USER, 2022-2031 (USD MILLION)
TABLE 12 AUSTRIA DIAGNOSTIC TESTING MARKET, BY END-USER, 2022-2031 (USD MILLION)
TABLE 13 GERMANY DIAGNOSTIC TESTING MARKET, BY MODE OF TESTING, 2022-2031 (USD MILLION)
TABLE 14 SWITZERLAND DIAGNOSTIC TESTING MARKET, BY MODE OF TESTING, 2022-2031 (USD MILLION)
TABLE 15 AUSTRIA DIAGNOSTIC TESTING MARKET, BY MODE OF TESTING, 2022-2031 (USD MILLION)
TABLE 16 GERMANY DIAGNOSTIC TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD MILLION)
TABLE 17 SWITZERLAND DIAGNOSTIC TESTING MARKET: BY SAMPLE TYPE, 2022-2031 (USD MILLION)
TABLE 18 AUSTRIA DIAGNOSTIC TESTING MARKET: BY SAMPLE TYPE, 2022-2031 (USD MILLION)
List of Figure
FIGURE 1 GERMANY, SWITZERLAND, AND AUSTRIA DIAGNOSTIC TESTING MARKET: SEGMENTATION
FIGURE 2 GERMANY, SWITZERLAND, AND AUSTRIA DIAGNOSTIC TESTING MARKET: DATA TRIANGULATION
FIGURE 3 GERMANY, SWITZERLAND, AND AUSTRIA DIAGNOSTIC TESTING MARKET: DROC ANALYSIS
FIGURE 4 GERMANY, SWITZERLAND, AND AUSTRIA DIAGNOSTIC TESTING MARKET: COUNTRYWISE MARKET ANALYSIS
FIGURE 5 GERMANY, SWITZERLAND, AND AUSTRIA DIAGNOSTIC TESTING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GERMANY, SWITZERLAND, AND AUSTRIA DIAGNOSTIC TESTING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GERMANY, SWITZERLAND, AND AUSTRIA DIAGNOSTIC TESTING MARKET: END-USER COVERAGE GRID
FIGURE 8 GERMANY, SWITZERLAND, AND AUSTRIA DIAGNOSTIC TESTING MARKET: DBMR MARKET POSITION GRID
FIGURE 9 GERMANY, SWITZERLAND, AND AUSTRIA DIAGNOSTIC TESTING MARKET: SEGMENTATION
FIGURE 10 SIX SEGMENTS COMPRISE THE GERMANY DIAGNOSTIC TESTING MARKET, BY TESTING
FIGURE 11 SIX SEGMENTS COMPRISE AUSTRIA DIAGNOSTIC TESTING MARKET, BY TESTING
FIGURE 12 SIX SEGMENTS COMPRISE THE SWITZERLAND DIAGNOSTIC TESTING MARKET, BY TESTING
FIGURE 13 EXECUTIVE SUMMARY
FIGURE 14 STRATEGIC DECISIONS
FIGURE 15 INCREASE IN THE NUMBER OF CHRONIC DISORDERS IS EXPECTED TO DRIVE THE GROWTH OF THE GERMANY, SWITZERLAND, AND AUSTRIA DIAGNOSTIC TESTING MARKET FROM 2024 TO 2031
FIGURE 16 THE TESTING SEGMENT, IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GERMANY, SWITZERLAND, AND AUSTRIA DIAGNOSTIC TESTING MARKET IN 2024 & 2031
FIGURE 17 GERMANY DIAGNOSTIC TESTING MARKET: BY TESTING, 2023
FIGURE 18 SWITZERLAND DIAGNOSTIC TESTING MARKET: BY TESTING, 2023
FIGURE 19 AUSTRIA DIAGNOSTIC TESTING MARKET: BY TESTING, 2023
FIGURE 20 GERMANY DIAGNOSTIC TESTING MARKET: BY TESTING, 2024-2031 (USD MILLION)
FIGURE 21 SWITZERLAND DIAGNOSTIC TESTING MARKET: BY TESTING, 2024-2031 (USD MILLION)
FIGURE 22 AUSTRIA DIAGNOSTIC TESTING MARKET: BY TESTING, 2024-2031 (USD MILLION)
FIGURE 23 GERMANY DIAGNOSTIC TESTING MARKET: BY TESTING, CAGR (2024-2031)
FIGURE 24 SWITZERLAND DIAGNOSTIC TESTING MARKET: BY TESTING, CAGR (2024-2031)
FIGURE 25 AUSTRIA DIAGNOSTIC TESTING MARKET: BY TESTING, CAGR (2024-2031)
FIGURE 26 GERMANY DIAGNOSTIC TESTING MARKET: BY TESTING, LIFELINE CURVE
FIGURE 27 SWITZERLAND DIAGNOSTIC TESTING MARKET: BY TESTING, LIFELINE CURVE
FIGURE 28 AUSTRIA DIAGNOSTIC TESTING MARKET: BY TESTING, LIFELINE CURVE
FIGURE 29 GERMANY DIAGNOSTIC TESTING MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 30 SWITZERLAND DIAGNOSTIC TESTING MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 31 AUSTRIA DIAGNOSTIC TESTING MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 32 GERMANY DIAGNOSTIC TESTING MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 33 SWITZERLAND DIAGNOSTIC TESTING MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 34 AUSTRIA DIAGNOSTIC TESTING MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 35 GERMANY DIAGNOSTIC TESTING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 36 SWITZERLAND DIAGNOSTIC TESTING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 37 AUSTRIA DIAGNOSTIC TESTING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 38 GERMANY DIAGNOSTIC TESTING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 39 SWITZERLAND DIAGNOSTIC TESTING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 40 AUSTRIA DIAGNOSTIC TESTING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 41 GERMANY DIAGNOSTIC TESTING MARKET: BY END USER, 2023
FIGURE 42 SWITZERLAND DIAGNOSTIC TESTING MARKET: BY END USER, 2023
FIGURE 43 AUSTRIA DIAGNOSTIC TESTING MARKET: BY END USER, 2023
FIGURE 44 GERMANY DIAGNOSTIC TESTING MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 45 SWITZERLAND DIAGNOSTIC TESTING MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 46 AUSTRIA DIAGNOSTIC TESTING MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 47 GERMANY DIAGNOSTIC TESTING MARKET: BY END USER, CAGR (2024-2031)
FIGURE 48 SWITZERLAND DIAGNOSTIC TESTING MARKET: BY END USER, CAGR (2024-2031)
FIGURE 49 AUSTRIA DIAGNOSTIC TESTING MARKET: BY END USER, CAGR (2024-2031)
FIGURE 50 GERMANY DIAGNOSTIC TESTING MARKET: BY END USER, LIFELINE CURVE
FIGURE 51 SWITZERLAND DIAGNOSTIC TESTING MARKET: BY END USER, LIFELINE CURVE
FIGURE 52 AUSTRIA DIAGNOSTIC TESTING MARKET: BY END USER, LIFELINE CURVE
FIGURE 53 GERMANY DIAGNOSTIC TESTING MARKET: BY MODE OF TESTING, 2023
FIGURE 54 SWITZERLAND DIAGNOSTIC TESTING MARKET: BY MODE OF TESTING, 2023
FIGURE 55 AUSTRIA DIAGNOSTIC TESTING MARKET: BY MODE OF TESTING, 2023
FIGURE 56 GERMANY DIAGNOSTIC TESTING MARKET: BY MODE OF TESTING, 2024-2031 (USD MILLION)
FIGURE 57 SWITZERLAND DIAGNOSTIC TESTING MARKET: BY MODE OF TESTING, 2024-2031 (USD MILLION)
FIGURE 58 AUSTRIA DIAGNOSTIC TESTING MARKET: BY MODE OF TESTING, 2024-2031 (USD MILLION)
FIGURE 59 GERMANY DIAGNOSTIC TESTING MARKET: BY MODE OF TESTING, CAGR (2024-2031)
FIGURE 60 SWITZERLAND DIAGNOSTIC TESTING MARKET: BY MODE OF TESTING, CAGR (2024-2031)
FIGURE 61 AUSTRIA DIAGNOSTIC TESTING MARKET: BY MODE OF TESTING, CAGR (2024-2031)
FIGURE 62 GERMANY DIAGNOSTIC TESTING MARKET: BY MODE OF TESTING, LIFELINE CURVE
FIGURE 63 SWITZERLAND DIAGNOSTIC TESTING MARKET: BY MODE OF TESTING, LIFELINE CURVE
FIGURE 64 AUSTRIA DIAGNOSTIC TESTING MARKET: BY MODE OF TESTING, LIFELINE CURVE
FIGURE 65 GERMANY DIAGNOSTIC TESTING MARKET: BY SAMPLE TYPE, 2023
FIGURE 66 SWITZERLAND DIAGNOSTIC TESTING MARKET: BY SAMPLE TYPE, 2023
FIGURE 67 AUSTRIA DIAGNOSTIC TESTING MARKET: BY SAMPLE TYPE, 2023
FIGURE 68 GERMANY DIAGNOSTIC TESTING MARKET: BY SAMPLE TYPE, 2024-2031 (USD MILLION)
FIGURE 69 SWITZERLAND DIAGNOSTIC TESTING MARKET: BY SAMPLE TYPE, 2024-2031 (USD MILLION)
FIGURE 70 AUSTRIA DIAGNOSTIC TESTING MARKET: BY SAMPLE TYPE, 2024-2031 (USD MILLION)
FIGURE 71 GERMANY DIAGNOSTIC TESTING MARKET: BY SAMPLE TYPE, CAGR (2024-2031)
FIGURE 72 SWITZERLAND DIAGNOSTIC TESTING MARKET: BY SAMPLE TYPE, CAGR (2024-2031)
FIGURE 73 AUSTRIA DIAGNOSTIC TESTING MARKET: BY SAMPLE TYPE, CAGR (2024-2031)
FIGURE 74 GERMANY DIAGNOSTIC TESTING MARKET: BY SAMPLE TYPE, LIFELINE CURVE
FIGURE 75 SWITZERLAND DIAGNOSTIC TESTING MARKET: BY SAMPLE TYPE, LIFELINE CURVE
FIGURE 76 AUSTRIA DIAGNOSTIC TESTING MARKET: BY SAMPLE TYPE, LIFELINE CURVE
FIGURE 77 GERMANY, SWITZERLAND, AND AUSTRIA DIAGNOSTIC TESTING MARKET: COMPANY SHARE 2023 (%)
